- Sung-wuk Kim, DDS.
CEO, ImmunoMet Therapeutics
Dr. Sung-wuk Kim has served as Chairman of the Board of Directors and Chief Executive Officer (CEO) since the founding of ImmunoMet Therapeutics, a spinoff of HanAll Biopharma in July 2015. Dr. Kim was previously the CEO of HanAll Biopharma, and during his 12 years in various executive positions, he led a variety of new drug development programs including autoimmune diseases, fibrosis and metabolic diseases. He also pioneered an OXPHOS inhibitor research platform that is designed to target cancer metabolism, which has produced ImmunoMet’s lead drug candidate, IM156. Dr. Kim is an entrepreneur and accomplished inventor, who has made significant contributions to advance drug development, receiving more than 30 patents in a broad range of areas which include formulation, biologics and small molecule drugs.
Dr. Kim has also currently served on the Board of Directors of HanAll Biopharma since 2003 and as Chair of the R&D Committee of Daewoong Pharma Group since 2015. Previously, he served on the Boards of Directors of Humasis Inc, a diagnostics kit development company from 2002 to 2015 and Hangen Biotech, a RSV vaccine development company from 2002 to 2004. Before devoting his career to drug development, Dr. Kim was the founder of an IT entrepreneurial company, Freechal Inc, first XML platform internet community service provider, in 1999 and served on its Board of Directors until 2002.
Dr. Kim earned his Doctorate of Dental Surgery from Yonsei University in Korea.
- Sungsoo Koh, PhD.
CFO, ImmunoMet Therapeutics
As the CFO of ImmunoMet, Dr. Koh brings 40 years of leadership and expertise in corporate research and finances and M&A. Dr. Koh also currently serves as the CEO of Intercapital Ltd., an investment firm he founded in 1997 and has established his leadership position in corporate growth strategy by closing mergers and acquisitions, financing deals, spin-offs, and listings for a number of companies in pharmaceuticals, biotech, high-tech and telecommunications sectors. Prior to Intercapital, Dr. Koh led the international business operation and equity research division of Hanhwa Securities. He began his career as an investment analyst of the electronics and pharmaceutical industries with Dongsuh Securities Ltd and started to develop his leadership in investment, international business operations and debt financing at the London office of Dongsuh Securities, which he established in 1985.Dr. Koh received his Ph.D. in Finance from City University London and MBA from University of Pittsburgh.
- Bongyong Lee, PhD.
Vice President, Daewoong Pharmaceuticals
Dr. Bongyong Lee has served as a member of our Board of Directors since ImmunoMet’s founding in July 2015. Dr. Lee currently serves as an Executive Vice President of Daewoong Pharmaceuticals, and on the Boards of Directors of HanAll Biopharma, Daewoong ENG and the Korean Pharmaceutical Society. He is also an adjunct professor of Severance Medical School, Yonsei University and the School of Pharmacy, Korea University.
Dr. Lee has been a dedicated scientist and leader in the biopharmaceutical field in Korea, with a distinguished career of more than 30 years of experience in new drug discovery. He has played a pivotal role in the development and commercialization of several drugs: Revoprazan, an acid pump antagonist; Nabota, a botulinum toxin under registration in the USA and EU; Meropenem, a broad-range antibiotic approved in the USA; Aricept patch, a medication launched in the EU for palliative treatment of Alzheimer disease. Dr. Lee is currently focused on the development of first-in-class drug compounds such as Nav1.7 antagonist and proline-tRNA synthase inhibitors. He has also played a key role as the Committee Chair for the "Pharma Korea 2020" Project, an innovative Korean government-sponsored project aimed at developing 20 new drugs under the Ministry of Welfare and Health.
He received the Korean Prime Minister’s Commendation Award in 2015 and the Outstanding Product-Development Award from the Korean FDA in 2007 for his achievements and contribution to drug development programs in Korea.
Dr. Lee earned his Ph.D. in Medicinal Chemistry from the School of Pharmacy, University of Buffalo.
- Jae Joon Kim
Director, Mirae Asset Venture Investments
Mr. Jae Joon Kim joined ImunoMet’s Board of Directors in March 2016. Mr. Kim is currently a Director of the Venture Investment Division of Korea-based Mirae Asset Venture Investments (Mirae Asset). Since 2009, he has been leading the Venture Investment Division of Mirae Asset and has successfully listed over 15 companies on the NASDAQ, KOSDAQ and KONEX stock market exchanges. He currently manages an equity investment portfolio comprised of more than 30 biopharmaceutical and medical diagnostics companies worldwide.
Mr. Kim has held several positions since joining Mirae Asset in 2006, including the Team Head of the Venture Investment Division and the Team Head of the Corporate Strategic Division.
Prior to joining Mirae Asset, from 2002 to 2006, Mr. Kim was a research associate at Macrogen, a Korea-based biotech company.
Mr. Kim earned a Master’s Degree from the Graduate School of Medicine, Korea University and a Bachelor of Science degree from Korea University.
Copyright © ImmunoMet. All rights reserved.